Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Multidrug-resistant urethritis caused by Haemophilus parainfluenzae: susceptibility pattern and fosfomycin as an alternative treatment.
Fidalgo BI, Iglesies J, García D, Vergara A, Fuertes de Vega I, Horvath L, Zboromyrska Y, Bosch J, González A, Riera-Monroig J, Roca I, Alguacil M, Casals-Pascual C, Pitart C, Mallolas J, Blanco JL, Espasa M. Fidalgo BI, et al. Among authors: riera monroig j. Sex Transm Infect. 2025 Jan 7:sextrans-2024-056142. doi: 10.1136/sextrans-2024-056142. Online ahead of print. Sex Transm Infect. 2025. PMID: 39773988 Free article. No abstract available.
Anti-IL-23 therapy for the treatment of moderate-to-severe inverse psoriasis: A 52-week multicentre study.
Ceravalls J, Ruiz-Villaverde R, Armesto S, Fernández-Armenteros JM, Riera-Monroig J, Gracia-Cazaña T, Quintana-Codina M, Iglesias-Sancho M, Salleras M, Moya AI, Melgosa Ramos FJ, Ferran M. Ceravalls J, et al. Among authors: riera monroig j. J Eur Acad Dermatol Venereol. 2024 Sep 13. doi: 10.1111/jdv.20346. Online ahead of print. J Eur Acad Dermatol Venereol. 2024. PMID: 39269142 No abstract available.
Real-world outcomes in patients with malignancy and moderate-to-severe psoriasis treated with guselkumab.
Gracia Cazaña T, Riera Monroig J, Izu R, Yanguas I, Lorda Espés M, Sánchez Salas MP, García Gil MF, Navarro Bielsa A, Aldea Manrique B, Almenara Blasco M, García-Latasa de Araníbar FJ, Fuentelsaz V, Morales Callaghan A, Ara-Martín M. Gracia Cazaña T, et al. Among authors: riera monroig j. JAAD Int. 2024 Apr 7;16:66-71. doi: 10.1016/j.jdin.2024.02.019. eCollection 2024 Sep. JAAD Int. 2024. PMID: 38774344 Free PMC article.
Certolizumab pegol effectiveness, survival and safety in patients with psoriasis: A multicenter retrospective analysis in daily clinical practice by the Spanish Psoriasis Group.
Sahuquillo-Torralba A, Mansilla-Polo M, Pujol-Marco C, Llamas-Velasco M, Rull EV, Ruiz Villaverde R, Ferran M, Pitarch G, Lopez A, Beltran E, Urruticoechea-Arana A, Riera-Monroig J, Alsina M, Vidal D, Belinchón Romero I, Notario J, Carrascosa JM, Gonzalez-Delgado V, Mollet J, Ribera M, Gallardo F. Sahuquillo-Torralba A, et al. Among authors: riera monroig j. Int J Dermatol. 2024 Dec;63(12):1720-1727. doi: 10.1111/ijd.17238. Epub 2024 May 12. Int J Dermatol. 2024. PMID: 38736107
Dose reduction is a feasible strategy in patients with plaque psoriasis who achieve sustained response with secukinumab: a retrospective, multicenter cohort study in daily practice setting.
Daudén E, Escario E, Martos-Cabrera L, Armesto S, Herrera-Acosta E, Vidal D, Vilarrasa E, Rivera R, de la Cueva P, Martorell A, Ballesca F, Belinchón I, Carretero G, Rodríguez L, Romero-Maté A, Pujol-Montcusí J, Salgado L, Sahuquillo-Torralba A, Coto-Segura P, Baniandrés O, Feltes R, Riera-Monroig J, Garrido J, Llamas-Velasco M. Daudén E, et al. Among authors: riera monroig j. Int J Dermatol. 2024 Apr;63(4):503-511. doi: 10.1111/ijd.16915. Epub 2024 Jan 2. Int J Dermatol. 2024. PMID: 38168847
Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real-life clinical practice.
Muñoz-Aceituno E, Butrón-Bris B, Ovejero-Benito MC, Sahuquillo-Torralba A, Baniandrés Rodríguez O, Herrera-Acosta E, Rivera-Diaz R, Ferran M, Sánchez-Carazo JL, Riera-Monroig J, Pujol-Montcusí J, Vidal D, de la Cueva P, García-Bustinduy M, Ruiz-Villaverde R, Ballescà F, Llamas-Velasco M, Navares M, Palomar-Moreno I, Sánchez-García I, García-Martínez J, Novalbos J, Zubiaur P, Abad-Santos F, Daudén-Tello E, de la Fuente H. Muñoz-Aceituno E, et al. Among authors: riera monroig j. J Eur Acad Dermatol Venereol. 2024 Sep;38(9):1783-1790. doi: 10.1111/jdv.19782. Epub 2023 Dec 28. J Eur Acad Dermatol Venereol. 2024. PMID: 38153843
Safety of biologic therapy in combination with methotrexate in moderate to severe psoriasis: a cohort study from the BIOBADADERM registry.
Lluch-Galcerá JJ, Carrascosa JM, González-Quesada A, Rivera-Díaz R, Sahuquillo-Torralba A, Llamas-Velasco M, Gómez-García FJ, Herrera-Acosta E, de la Cueva P, Baniandrés-Rodríguez O, Lopez-Estebaranz JL, Belinchón I, Ferrán M, Mateu A, Rodríguez L, Riera-Monroig J, Abalde-Pintos MT, Carretero G, García-Donoso C, Pujol-Marco C, Del Alcázar E, Santamaría-Domínguez C, Suárez-Pérez JA, Nieto-Benito LM, Ruiz-Genao DP, Salgado-Boquete L, Descalzo MÁ, García-Doval I. Lluch-Galcerá JJ, et al. Among authors: riera monroig j. Br J Dermatol. 2024 Feb 16;190(3):355-363. doi: 10.1093/bjd/ljad382. Br J Dermatol. 2024. PMID: 37846976
47 results